SOURCE: UV Flu Technologies, Inc.

UV Flu Technologies, Inc.

October 21, 2010 06:00 ET

UV Flu Technologies Completes Production of "Designing Spaces / Holiday Spaces" TV Segment Featuring ViraTech UV-400 Air Purifier

Broadcast Targets Solution for Indoor Air Quality During Holiday Flu and Cold Season

CENTERVILLE, MA--(Marketwire - October 21, 2010) -  UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce that the Company has recently completed taping a segment of the "Designing Spaces" TV Show featuring its flagship ViraTech UV-400 air purification system, which is slated for national broadcast in late November and again in early December. The show, to be aired on the Women's Entertainment channel, focuses on holiday season health issues and is expected to reach up to 75 million households. Exact dates and times will be made available on the Company website shortly.

The theme of the segment is about staying healthy indoors over the holidays, and the UV-400 offers thought-provoking interest for health conscious consumers. The show provides insights into the UV-400's listing as a Medical Device as a result of rigorous laboratory tests which have conclusively proven that the product kills 99% of airborne bacteria in its patented UV chamber. The UV-400 is designed to easily circulate and filter the air within the average home or work environment multiple times per hour, and this will be demonstrated with real life situations and applications during the television presentation.

Given the amount of time people spend indoors during the Holidays, the show notes that not all health issues come as a result of exposure to bacteria. Many volatile compounds are regularly found in furniture, cleaning supplies, building materials, insecticides, and even common household items like hairspray. Poor indoor air quality can lead to increases in allergic reactions and other forms of respiratory problems. The alleviation of these problems will be examined and just how the UV-400 purifies the air of these irritants will be shown.

"We hope to educate people to the many dangers associated with poor indoor air quality, and also that our UV-400 is a very cost-effective way to protect themselves. We believe this show is a tremendous platform to reach one of our key markets: concerned parents who value the health of their families," stated John J. Lennon President of UV Flu Technologies.

Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.

About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. ViraTech UV-400 is a Class II medical device and is available without a prescription. 

Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

ON BEHALF OF THE BOARD

UV Flu Technologies, Inc.

John J. Lennon, President & CEO

Contact Information